Epigenetics of human melanoma: Promises and challenges

Journal of Molecular Cell Biology

Volumn 6, Issue 5, 2014, Pages

  Besaratinia, Ahmad ^a   Tommasi, Stella ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aberrant DNA methylation; Epigenetic therapy; Histone modifications; Melanoma cell lines; Skin cancer

Indexed keywords

CANCER EPIDEMIOLOGY; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; HEREDITY; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; NONHUMAN; PYROSEQUENCING; REVIEW; SOLID TUMOR; CARCINOGENESIS; GENETIC EPIGENESIS; GENETICS; METABOLISM;

HISTONE;

CARCINOGENESIS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MELANOMA;

EID: 84928779208     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mju027     Document Type: Review

References (92)

1. American Cancer Society. (2013). Cancer Facts & Figures, 2013. Atlanta, GA.
2. Azad, N., Zahnow, C.A., Rudin, C.M., et al. (2013). The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol. 10, 256-266.
3. Baylin, S.B., and Jones, P.A. (2011). A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11, 726-734.
4. Besaratinia, A., and Pfeifer, G.P. (2008). Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum. Mutat. 29, 983-991.
5. Besaratinia, A., Kim, S.I., and Pfeifer, G.P. (2008). Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells. FASEB J. 22, 2379-2392.
6. Besaratinia, A., Cockburn, M., and Tommasi, S. (2013). Alterations of DNA methylome in human bladder cancer. Epigenetics 8, 1013-1022.
7. Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21.
8. Bird, A., and Macleod, D. (2004). Reading the DNA methylation signal. Cold Spring Harb. Symp. Quant. Biol. 69, 113-118.
9. Cannuyer, J., Loriot, A., Parvizi, G.K., et al. (2013). Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications. PLoS One 8, e58743.
10. Cherblanc, F., Chapman-Rothe, N., Brown, R., et al. (2012). Current limitations and future opportunities for epigenetic therapies. Future Med. Chem. 4, 425-446.
11. Chin, L., Garraway, L.A., and Fisher, D.E. (2006). Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149-2182.
12. Chung, W., Bondaruk, J., Jelinek, J., et al. (2011). Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev. 20, 1483-1491.
13. Clements, E.G., Mohammad, H.P., Leadem, B.R., et al. (2012). DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res. 40, 4334-4346.
14. Conway, K., Edmiston, S.N., Khondker, Z.S., et al. (2011). DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res. 24, 352-360.
15. V600E cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
16. Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27.
17. DeCarvalho, D.D., Sharma, S., You, J.S., et al. (2012). DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 21, 655-667.
18. De Smet, C., and Loriot, A. (2013). DNA hypomethylation and activation of germline-specific genes in cancer. Adv. Exp. Med. Biol. 754, 149-166.
19. Deaton, A.M., and Bird, A. (2011). CpG islands and the regulation of transcription. Genes Dev. 25, 1010-1022.
20. Devitt, B., Liu, W., Salemi, R., et al. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 24, 666-672.
21. Doi, A., Park, I.H., Wen, B., et al. (2009). Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41, 1350-1353.
22. Ehrlich, M. (2009). DNA hypomethylation in cancer cells. Epigenomics 1, 239-259.
23. Estecio, M.R., and Issa, J.P. (2009). Tackling the methylome: recent methodological advances in genome-wide methylation profiling. Genome Med. 1, 106.
24. Esteller, M. (2008). Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159.
25. Fecher, L.A., Cummings, S.D., Keefe, M.J., et al. (2007). Toward a molecular classification of melanoma. J. Clin. Oncol. 25, 1606-1620.
26. Feinberg, A.P., and Tycko, B. (2004). The history of cancer epigenetics. Nat. Rev. Cancer 4, 143-153.
27. Feinberg, A.P., and Vogelstein, B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92.
28. Flaherty, K.T., Hodi, F.S., and Fisher, D.E. (2012). From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12, 349-361.
29. Gal-Yam, E.N., Saito, Y., Egger, G., et al. (2008). Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 59, 267-280.
30. Garibyan, L., and Fisher, D.E. (2010). How sunlight causes melanoma. Curr. Oncol. Rep. 12, 319-326.
31. Gius, D., Cui, H., Bradbury, C.M., et al. (2004). Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6, 361-371.
32. Grant, W.B., Garland, C.F., and Holick, M.F. (2005). Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem. Photobiol. 81, 1276-1286.
33. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
34. Griewank, K.G., Ugurel, S., Schadendorf, D., et al. (2013). New developments in biomarkers for melanoma. Curr. Opin. Oncol. 25, 145-151.
35. Gronbaek, K., Hother, C., and Jones, P.A. (2007). Epigenetic changes in cancer. APMIS 115, 1039-1059.
36. Guil, S., and Esteller, M. (2009). DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem. Cell Biol. 41, 87-95.
37. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
38. Hansen, K.D., Timp, W., Bravo, H.C., et al. (2011). Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768-775.
39. Hinoue, T., Weisenberger, D.J., Lange, C.P., et al. (2012). Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2, 271-282.
40. Howell, P.M., Jr, Liu, S., Ren, S., et al. (2009). Epigenetics in human melanoma. Cancer Control 16, 200-218.
41. Illingworth, R., Kerr, A., Desousa, D., et al. (2008). A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 6, e22.
42. Irizarry, R.A., Ladd-Acosta, C., Wen, B., et al. (2009). The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178-186.
43. Issa, J.P. (2004). CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4, 988-993.
44. Izzo, A., and Schneider, R. (2010). Chatting histone modifications in mammals. Brief. Funct. Genomics 9, 429-443.
45. Jacinto, F.V., Ballestar, E., and Esteller, M. (2009). Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation. Oncogene 28, 4212-4224.
46. Jin, B., Li, Y., and Robertson, K.D. (2011). DNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer 2, 607-617.
47. Jones, P.A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484-492.
48. Jones, P.A., and Liang, G. (2009). Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 10, 805-811.
49. Kelly, T.K., De Carvalho, D.D., and Jones, P.A. (2010). Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28, 1069-1078.
50. Ko, J.M., and Fisher, D.E. (2011). A new era: melanoma genetics and therapeutics. J. Pathol. 223, 241-250.
51. Kondo, Y., Shen, L., Cheng, A.S., et al. (2008). Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40, 741-750.
52. Kulis, M., and Esteller, M. (2010). DNA methylation and cancer. Adv. Genet. 70, 27-56.
53. La Porta, C.A. (2012). Melanoma and epigenetic treatment: past and future. Anticancer Agents Med. Chem. 12, 202-209.
54. Laird, P.W. (2010). Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 11, 191-203.
55. Lian, C.G., Xu, Y., Ceol, C., et al. (2012). Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135-1146.
56. Little, E.G., and Eide, M.J. (2012). Update on the current state of melanoma incidence. Dermatol. Clin. 30, 355-361.
57. Loriot, A., De Plaen, E., Boon, T., et al. (2006). Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem. 281, 10118-10126.
58. Lucas, R., McMichael, T., Smith, W., et al. (2006). Solar ultraviolet radiation: global burden of disease from solar radiation. In Prüss-Üstün, A., Zeeb, H., Mathers, C., et al. (eds). Environmental Burden of Disease Series, no 13. Geneva: World Health Organization, 250.
59. Maunakea, A.K., Nagarajan, R.P., Bilenky, M., et al. (2010). Conserved role of intragenic DNA methylation inregulating alternative promoters. Nature 466, 253-257.
60. Miller, A.J., and Mihm, M.C., Jr. (2006). Melanoma. N. Engl. J. Med. 355, 51-65.
61. Molognoni, F., Cruz, A.T., Meliso, F.M., et al. (2011). Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics 6, 450-464.
62. Momparler, R.L. (2005). Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin. Oncol. 32, 443-451.
63. Mori, T., Kim, J., Yamano, T., et al. (2005). Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res. 65, 1800-1807.
64. Nagarajan, R.P., and Costello, J.F. (2009). Epigenetic mechanisms in glioblastoma multiforme. Semin. Cancer Biol. 19, 188-197.
65. Pan, L., Pan, H., Jiang, H., et al. (2010). HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp 1. Cell. Mol. Immunol. 7, 221-226.
66. Patino, W.D., and Susa, J. (2008). Epigenetics of cutaneous melanoma. Adv. Dermatol. 24, 59-70.
67. Patton, E.E., Widlund, H.R., Kutok, J.L., et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254.
68. Pimiento, J.M., Larkin, E.M., Smalley, K.S., et al. (2013). Melanoma genotypes and phenotypes get personal. Lab. Invest. 93, 858-867.
69. Popovic, R., and Licht, J.D. (2012). Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2, 405-413.
70. Portela, A., and Esteller, M. (2010). Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057-1068.
71. Rhee, I., Bachman, K.E., Park, B.H., et al. (2002). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552-556.
72. Ries, L.A.G., Eisner, M.P., Kosary, C.L., et al. (2004). SEER Cancer Statistics Review, 1975-2001. Bethesda: National Cancer Institute.
73. Rodriguez-Cerdeira, C., and Molares-Vila, A. (2011). New perspectives of "omics" applications in melanoma research. Open Biochem. J. 5, 60-66.
74. Rodriguez-Paredes, M., and Esteller, M. (2011). Cancer epigenetics reaches mainstream oncology. Nat. Med. 17, 330-339.
75. Schones, D.E., and Zhao, K. (2008). Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 9, 179-191.
76. Shen, H., and Laird, P.W. (2013). Interplay between the cancer genome and epigenome. Cell 153, 38-55.
77. Sigalotti, L., Covre, A., Fratta, E., et al. (2010). Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J. Transl. Med. 8, 56.
78. Sigalotti, L., Covre, A., Fratta, E., et al. (2012). Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J. Transl. Med. 10, 185.
79. Spugnardi, M., Tommasi, S., Dammann, R., et al. (2003). Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 63, 1639-1643.
80. Suzuki, M.M., and Bird, A. (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9, 465-476.
81. Tanaka, R., Koyanagi, K., Narita, N., et al. (2011). Prognostic molecular biomarkers for cutaneous malignant melanoma. J. Surg. Oncol. 104, 438-446.
82. Tanemura, A., Terando, A.M., Sim, M.S., et al. (2009). CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15, 1801-1807.
83. Tellez, C.S., Shen, L., Estecio, M.R., et al. (2009). CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 19, 146-155.
84. Thomson, J.P., Skene, P.J., Selfridge, J., et al. (2010). CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 464, 1082-1086.
85. Tommasi, S., Zheng, A., Yoon, J.I., et al. (2014). Epigenetic targeting of the Nanog pathway and signaling networks during chemical carcinogenesis. Carcinogenesis, doi: 10.1093/carcin/bgu026.
86. Tsai, H.C., and Baylin, S.B. (2011). Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 21, 502-517.
87. Tsao, H., Chin, L., Garraway, L.A., et al. (2012). Melanoma: from mutations to medicine. Genes Dev. 26, 1131-1155.
88. van den Hurk, K., Niessen, H.E., Veeck, J., et al. (2012). Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim. Biophys. Acta 1826, 89-102.
89. Wilson, A.S., Power, B.E., and Molloy, P.L. (2007). DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775, 138-162.
90. Wolff, E.M., Chihara, Y., Pan, F., et al. (2010). Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 70, 8169-8178.
91. Yang, X., Lay, F., Han, H., et al. (2010). Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 31, 536-546.
92. Zhou, V.W., Goren, A., and Bernstein, B.E. (2011). Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 12, 7-18.